Eylea 2 mg

Aflibercept, the active ingredient in Eylea 2 mg, is a VEGF inhibitor presented as a 2 mg solution for intravitreal use. It is used to treat various eye conditions involving abnormal blood vessel growth in adults and premature infants. GNH USA supplies Eylea 2 mg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Eylea 2 mg is specifically designed to address conditions that affect the retina, a critical part of the eye responsible for vision. This medication is administered directly into the vitreous humor of the eye to target and inhibit the growth of abnormal blood vessels.

Eylea 2 mg is used to treat conditions related to abnormal blood vessel growth in the retina. It is indicated for the following:

- Neovascular age-related macular degeneration: Reduces the growth of abnormal blood vessels in the retina, preventing vision loss. - Macular edema secondary to retinal vein occlusion: Decreases swelling in the macula caused by blocked veins in the retina. - Diabetic macular edema: Helps to reduce swelling in the macula due to diabetic retinopathy. - Myopic choroidal neovascularization: Treats abnormal blood vessel growth in the choroid, a layer of the eye, due to severe myopia.

Eylea 2 mg, like all medications, can cause side effects. Common Side Effects: - Eye pain or redness at the injection site. - Increased floaters in the vision. - Conjunctival hemorrhage (small bleeding spots in the eye). - Cataracts or increased intraocular pressure.

Serious or Rare Side Effects: - Endophthalmitis (severe eye infection). - Retinal detachment (separation of the retina from the back of the eye). - Increased risk of arterial thromboembolic events (e.g., heart attack or stroke). - Severe vision loss or blindness.

Eylea 2 mg should be used with caution and under the supervision of a healthcare professional. Important precautions include: - Informed consent: Ensure the patient understands the risks and benefits of the treatment. - Monitoring: Regular eye examinations are necessary to monitor for side effects and treatment efficacy. - Infection risk: The injection site must be kept clean to prevent infection. - Pre-existing conditions: Patients with a history of eye infections or inflammation should be closely monitored. - Pregnancy and breastfeeding: The safety of Eylea 2 mg during pregnancy and breastfeeding is not established. - Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Eylea 2 mg may interact with other medications, requiring careful management. Major Interactions (Avoid): - Other intravitreal agents: Avoid concurrent use with other intravitreal medications to prevent adverse interactions. - Systemic anti-VEGF therapies: Avoid combining with systemic VEGF inhibitors to reduce the risk of systemic side effects.

Moderate Interactions (Monitor Closely): - Immunosuppressants: Monitor for increased risk of infections when used with immunosuppressant drugs. - Anticoagulants: Closely monitor for signs of bleeding or thromboembolic events. - Anti-inflammatory drugs: Monitor for increased risk of eye inflammation or infection.